Intercept Pharmaceuticals (ICPT) Receives Breakthrough Therapy Designation from FDA

Shares of Intercept Pharmaceuticals Inc. (ICPT) were up +57.31 or +33.58 percent to $228.00 per share in pre-market trading on Thursday, after the company announced late yesterday its investigational product, obeticholic acid (OCA) had received “breakthrough therapy designation” from the U.S. Food and Drug Administration (FDA) for the treating patients with nonalcoholic steatohepatitis (NASH). Intercept Read the full article... Read the rest of Intercept Pharmaceuticals (ICPT) Receives Breakthrough Therapy Designation from FDA at InvestorGuide.com .